AP2002002531A0 - 4-Carboboxyamino-2-ethyl-1,2,3,4-tetrahydroquinoline crystal as cetp inihibitor. - Google Patents

4-Carboboxyamino-2-ethyl-1,2,3,4-tetrahydroquinoline crystal as cetp inihibitor.

Info

Publication number
AP2002002531A0
AP2002002531A0 APAP/P/2002/002531A AP2002002531A AP2002002531A0 AP 2002002531 A0 AP2002002531 A0 AP 2002002531A0 AP 2002002531 A AP2002002531 A AP 2002002531A AP 2002002531 A0 AP2002002531 A0 AP 2002002531A0
Authority
AP
ARIPO
Prior art keywords
carboboxyamino
inihibitor
cetp
tetrahydroquinoline
ethyl
Prior art date
Application number
APAP/P/2002/002531A
Other languages
English (en)
Inventor
Douglas John Meldrum Allen
Troy Anthony Appleton
Lyle R Brostrom
Derek Lawrence Tickner
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of AP2002002531A0 publication Critical patent/AP2002002531A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Child & Adolescent Psychology (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Cephalosporin Compounds (AREA)
  • Quinoline Compounds (AREA)
APAP/P/2002/002531A 1999-11-30 2000-11-14 4-Carboboxyamino-2-ethyl-1,2,3,4-tetrahydroquinoline crystal as cetp inihibitor. AP2002002531A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16805199P 1999-11-30 1999-11-30
PCT/IB2000/001650 WO2001040190A1 (en) 1999-11-30 2000-11-14 4-carboxyamino-2-ethyl-1,2,3,4-tetrahydroquinoline crystal as cetp inhibitor

Publications (1)

Publication Number Publication Date
AP2002002531A0 true AP2002002531A0 (en) 2002-06-30

Family

ID=22609901

Family Applications (1)

Application Number Title Priority Date Filing Date
APAP/P/2002/002531A AP2002002531A0 (en) 1999-11-30 2000-11-14 4-Carboboxyamino-2-ethyl-1,2,3,4-tetrahydroquinoline crystal as cetp inihibitor.

Country Status (28)

Country Link
EP (1) EP1246804A1 (is)
JP (1) JP2003515592A (is)
KR (1) KR20020058057A (is)
CN (1) CN1402711A (is)
AP (1) AP2002002531A0 (is)
AU (1) AU1048801A (is)
BG (1) BG106854A (is)
BR (1) BR0015836A (is)
CA (1) CA2392979A1 (is)
CO (1) CO5271716A1 (is)
EA (1) EA200200510A1 (is)
EC (1) ECSP003792A (is)
EE (1) EE200200277A (is)
GT (1) GT200000199A (is)
HU (1) HUP0203521A2 (is)
IL (1) IL149097A0 (is)
IS (1) IS6338A (is)
MA (1) MA26845A1 (is)
MX (1) MXPA02005354A (is)
NO (1) NO20022558D0 (is)
OA (1) OA12099A (is)
PA (1) PA8506301A1 (is)
PE (1) PE20010904A1 (is)
PL (1) PL355892A1 (is)
TN (1) TNSN00231A1 (is)
TR (1) TR200201446T2 (is)
UY (1) UY26454A1 (is)
WO (1) WO2001040190A1 (is)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7115279B2 (en) 2000-08-03 2006-10-03 Curatolo William J Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors
WO2003000295A2 (en) * 2001-06-21 2003-01-03 Pfizer Products Inc. Self-emulsifying formulations of cholesteryl ester transfer protein inhibitors
GT200200170A (es) 2001-09-28 2003-05-23 Preparacion de inhibidor de cetp anhidro
EP1920766B1 (en) * 2002-02-01 2017-08-23 Bend Research, Inc Pharmaceutical compositions of amorphous dispersions of drugs and lipophilic microphase-forming materials
EP1469833B1 (en) * 2002-02-01 2021-05-19 Bend Research, Inc. Method for making homogeneous spray-dried solid amorphous drug dispersions utilizing modified spray-drying apparatus
ATE395044T1 (de) 2002-02-01 2008-05-15 Pfizer Prod Inc Pharmazeutische zusammensetzungen amorpher dispersionen von wirkstoffen und lipophiler mikrophasenbildender materialien
BR0306208A (pt) 2002-08-30 2004-10-13 Japan Tobacco Inc Compostos de dibenzilamina e seu uso farmacêutico
AU2003277285B2 (en) 2002-10-04 2007-12-13 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
US7504508B2 (en) 2002-10-04 2009-03-17 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
EP1961419B1 (en) 2002-12-20 2010-03-24 Pfizer Products Inc. Dosage forms comprising a CETP inhibitor and an HMG-CoA reductase inhibitor
US20040132771A1 (en) * 2002-12-20 2004-07-08 Pfizer Inc Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors
WO2004082675A1 (en) 2003-03-17 2004-09-30 Japan Tobacco Inc. Method for increasing the oral bioavailability of s-[2- ([[1- (2-ethylbutyl) cyclohexyl] carbonyl] amino) phenyl] 2-methylpropanethioate
KR100729883B1 (ko) * 2003-03-28 2007-06-18 화이자 프로덕츠 인코포레이티드 죽상경화증 및 비만증을 치료하기 위한 ｃｅｔｐ억제제로서의 1,2,4-치환된 1,2,3,4-테트라하이드로- 및1,2-디하이드로-퀴놀린 및1,2,3,4-테트라하이드로-퀴녹살린 유도체
JP2007501218A (ja) 2003-08-04 2007-01-25 ファイザー・プロダクツ・インク 非晶質薬物の吸着物および親油性ミクロ相形成物質の医薬組成物
WO2005037796A1 (en) 2003-10-08 2005-04-28 Eli Lilly And Company Compounds and methods for treating dyslipidemia
CN1942428A (zh) * 2004-04-13 2007-04-04 默克公司 Cetp抑制剂
AU2005267436A1 (en) * 2004-06-24 2006-02-02 Eli Lilly And Company Compounds and methods for treating dyslipidemia
WO2006033001A1 (en) * 2004-09-23 2006-03-30 Pfizer Products Inc. Quinoline compounds
US20070149567A1 (en) * 2004-09-23 2007-06-28 Pfizer Inc Quinoline compounds
UA90706C2 (ru) 2005-02-24 2010-05-25 Милленниум Фармасьютикалз, Инк. Антагонисты рецептора pgd2 для лечения воспалительных заболеваний
WO2006098394A1 (ja) * 2005-03-14 2006-09-21 Japan Tobacco Inc. 脂質吸収抑制方法および脂質吸収抑制剤
US7737155B2 (en) 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
AR065670A1 (es) 2007-03-09 2009-06-24 Indigene Pharmaceuticals Inc Combinacion de metformina r-(+) lipoato y agentes antihiperlipidemicos para el tratamiento de hiperglucemia diabetica y complicaciones diabeticas
US20110245209A1 (en) 2008-12-16 2011-10-06 Schering Corporation Pyridopyrimidine derivatives and methods of use thereof
WO2010075069A1 (en) 2008-12-16 2010-07-01 Schering Corporation Bicyclic pyranone derivatives as nicotinic acid receptor agonists
AR077208A1 (es) 2009-06-30 2011-08-10 Lilly Co Eli Derivados del acido trans-4-[[(5s)-5-[[[3,5-bis(trifluorometil) fenil] metil] (2-metil-2h-tetrazol-5-il) amino) -2,3,4,5-tetrahidro-7,9-dimetil-1h-1-benzazepin-1-il) metil)-ciclohexancarboxilico y sus formas cristalinas, composiciones farmaceuticas que los comprenden, su uso para preparar un medicam
RU2703192C2 (ru) 2014-07-30 2019-10-15 Ф. Хоффманн-Ля Рош Аг Генетические маркеры для прогнозирования ответа на терапию поднимающими уровень hdl или имитирующими hdl агентами

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5231102A (en) * 1989-03-08 1993-07-27 Merck Sharp & Dohme, Ltd. Tetrahydroquinoline derivatives useful for neurodegenerative disorders
AU5731098A (en) * 1997-02-03 1998-08-25 American Home Products Corporation 2-substituted-1-acyl-1,2-dihydroquinoline derivatives to increase hdl-cholesterol level
US6197786B1 (en) * 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines

Also Published As

Publication number Publication date
IL149097A0 (en) 2002-11-10
PL355892A1 (en) 2004-05-31
EE200200277A (et) 2003-10-15
UY26454A1 (es) 2001-07-31
BR0015836A (pt) 2002-08-06
IS6338A (is) 2002-04-12
ECSP003792A (es) 2002-04-23
PE20010904A1 (es) 2001-09-10
WO2001040190A1 (en) 2001-06-07
TR200201446T2 (tr) 2002-11-21
NO20022558L (no) 2002-05-29
NO20022558D0 (no) 2002-05-29
CO5271716A1 (es) 2003-04-30
AU1048801A (en) 2001-06-12
BG106854A (bg) 2002-12-29
JP2003515592A (ja) 2003-05-07
GT200000199A (es) 2002-05-23
OA12099A (en) 2006-05-04
EA200200510A1 (ru) 2002-10-31
PA8506301A1 (es) 2002-08-26
TNSN00231A1 (fr) 2002-05-30
CN1402711A (zh) 2003-03-12
EP1246804A1 (en) 2002-10-09
KR20020058057A (ko) 2002-07-12
MA26845A1 (fr) 2004-12-20
HUP0203521A2 (hu) 2003-02-28
MXPA02005354A (es) 2002-12-11
CA2392979A1 (en) 2001-06-07

Similar Documents

Publication Publication Date Title
AP2002002531A0 (en) 4-Carboboxyamino-2-ethyl-1,2,3,4-tetrahydroquinoline crystal as cetp inihibitor.
YU74500A (sh) Novi derivat 3-aril-2-hidroksipropionske kiseline (i)
EP0789578A4 (en) MULTICATALYTIC PROTEASE INHIBITORS
FR05C0045I2 (is)
HU9302795D0 (en) Fungide compositions containing 2-(substituted phenyl)-ester of 3-metoxi-propenoic acid
CA2379747A1 (en) Novel succinate derivative compounds useful as cysteine protease inhibitors
AU5751299A (en) Piperizine-4-phenyl derivatives as inhibitors of the interaction between mdm2 and 53
CA2189007A1 (en) Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudormophs thereof
GR3033661T3 (en) Novel mercaptoacetylamido 1,3,4,5-tetrahydro-benzo(c)azepin-3-one disulfide derivatives useful as inhibitors of enkephalinase and ace
AU635415B2 (en) Use of n-alkyl-lactams as crystallization inhibitors
WO2000059285A3 (en) NOVEL LACTAM INHIBITORS OF MATRIX METALLOPROTEINASES, TNF-α, AND AGGRECANASE
FI934298A0 (fi) Kristallin tiagabine-hydrokloridmonohydrat, dess framstaellning och dess anvaendning
NZ331875A (en) Asymmetric synthesis of R-alpha-propyl-piperonyl amine and its analogs
TW252979B (is)
CA2024162A1 (en) Benzazabicyclo carbamates as novel cholinesterase inhibitors
PH21322A (en) Anti-imflammatory polymorphic monoethanolamine salt of n-(2-pyridyl)-2-methyl-4-hydroxy-2h-1,2-benzothiazine-3-carboxamide 1,1-dioxide compound; composition and method of use therefor
GR3029590T3 (en) Crystalline, polymorphic form of (s,s,s)-n-(1- 2-carboxy-3-(n?2 -mesyllysylamino)propyl]-1-cyclopentylcarbonyl)tyrosine
EP1118615A4 (en) PYRIDOPYRAZINE DERIVATIVES SALTS AND CRYSTALS THEREOF
BG104554A (en) Thermodynamically stable form of (r)-3-[(-4-fluorophenyl) sulphonyl]amino 1,2,3,4-tetrahydro-9h-carbazole-9-propanoic acid (ramatroban)
WO2001030759A3 (en) Sodium-hydrogen exchanger type 1 inhibitor crystals
MXPA05007696A (es) Modificacion cristalina de un complejo de manganeso.
IL140919A0 (en) N-substituted azabicycloheptane derivatives, production and use thereof
IL132344A0 (en) Alkaloid halide salts of swainsonine compositions containing the same and the use thereof